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Abstract
Background: 14-3-3epsilon regulates a wide range of biological processes, including cell cycle control, proliferation, 
and apoptosis, and plays a significant role in neurogenesis and the formation of malignant tumours. However, the 
exact function and regulatory mechanism of 14-3-3epsilon in carcinogenesis have not been elucidated.
Methods: The expression of 14-3-3epsilon was assessed by RT-PCR and western blotting. The invasiveness and viability 
of Hep-2 cells were determined by the transwell migration assay and MTT assay, respectively. Cell cycle and apoptosis 
of Hep-2 cells were detected by flow cytometry.
Results: The mRNA and protein expression of 14-3-3epsilon in larynx squamous cell carcinoma (LSCC) tissues were 
significantly lower than those in clear surgical margin tissues. Statistical analysis showed that the 14-3-3epsilon protein 
level in metastatic lymph nodes was lower than that in paired tumour tissues. In addition, the protein level of 14-3-
3epsilon in stage III or IV tumours was significantly lower than that in stage I or II tumours. Compared with control Hep-
2 cells, the percentages of viable cells in the 14-3-3epsilon-GFP and negative control GFP groups were 36.68 ± 14.09% 
and 71.68 ± 12.10%, respectively. The proportions of S phase were 22.47 ± 3.36%, 28.17 ± 3.97% and 46.15 ± 6.82%, and 
the apoptotic sub-G1 populations were 1.23 ± 1.02%, 2.92 ± 1.59% and 13.72 ± 3.89% in the control, negative control 
GFP and 14-3-3epsilon-GFP groups, respectively. The percentages of the apoptotic cells were 0.84 ± 0.25%, 1.08 ± 
0.24% and 2.93 ± 0.13% in the control, negative control GFP and 14-3-3epsilon-GFP groups, respectively. The numbers 
of cells that penetrated the filter membrane in the control, negative control GFP and 14-3-3epsilon-GFP groups were 
20.65 ± 1.94, 17.63 ± 1.04 and 9.1 ± 0.24, respectively, indicating significant differences among the different groups.
Conclusions: Decreased expression of 14-3-3epsilon in LSCC tissues contributes to the initiation and progression of 
LSCC. 14-3-3epsilon can promote apoptosis and inhibit the invasiveness of LSCC.
Background
Squamous cell carcinoma of the head and neck (SCCHN)
is considered the sixth most common cancer in the world
[1]. More than a half-million new cases of head and neck
cancers are reported annually worldwide [2]. Larynx
squamous cell carcinoma (LSCC) constitutes almost 2%
to 3% of all malignant tumours, representing the second
most common malignant neoplasm of the respiratory
tract [3]. Each year, around 700 new cases of LSCC in the
Netherlands [4] and 10,000 cases in the United States [5]
are diagnosed. In China, the incidence of LSCC has been
rising gradually, especially in the Northeast. The data
mentioned above indicate that laryngeal cancer has
become one of the most important cancers impairing
human life.
Risk factors such as smoking and alcohol abuse are
a s s o c i a t e d  w i t h  t h e  d e v e l o p m e n t  o f  L S C C  [ 6 ] .  E a r l y
laryngeal cancer can usually be managed successfully
with either radiotherapy or surgery. Advanced stage can-
cer often requires a combination of treatment modalities.
Depending on tumour stage, the local recurrence rate
varies from 10 to 50% [4]. Until now, total laryngectomy
or laryngopharyngectomy remains the procedure of
choice for advanced stage laryngeal carcinoma around
the world [7].
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Carcinogenesis involves complex processes including
many types of genetic changes, such as the activation of
oncogenes and the inactivation of tumour suppressor
genes [8]. With the development of molecular biology,
there is potential for the use of biomarkers in the diagno-
sis of LSCC in the future and the results from the study of
the molecular mechanisms of LSCC will provide useful
biomarkers of LSCC. At present, the biological targets
required for diagnosis of LSCC are still unknown.
In our previous study, we screened and identified sev-
eral proteins, including tyrosine 3-monooxygenase/tryp-
tophan 5-monooxygenase activation protein (14-3-
3epsilon), related to DNA methylation in laryngeal carci-
noma Hep-2 cells treated with 5-aza-2'-deoxycitydine (5-
Aza-CdR). 14-3-3epsilon is one of the mammalian 14-3-3
protein family members that contain a few regions of
diversity and have been proposed to interact with more
than 200 proteins [9].
14-3-3epsilon is a small acidic protein of about 30 kDa
that has the highest homology and is one of the most con-
served proteins in organic evolution. 14-3-3epsilon regu-
lates diverse biological processes, including cell cycle
control, proliferation, and apoptosis, and plays a signifi-
cant role in neurogenesis and the formation of malignant
tumours. However, the exact function and regulatory
mechanism of 14-3-3epsilon in carcinogenesis are not
clear. In this study, we explored the role of 14-3-3epsilon
in the development and aggression of LSCC by analysing
the expression and biological characteristics of 14-3-
3epsilon in LSCC.
Methods
Samples
One hundred one cases of LSCC tissues were obtained
from patients treated at the Ear, Nose and Throat (E.N.T)
Department of the 463 Hospital of PLA of China after
receiving their informed consent and the approval of the
hospital authorities. None of the patients received radio-
therapy or chemotherapy prior to the genetic analysis.
The clinical pathological characteristics of the patients
were evaluated according to the International Union
Against Cancer guidelines. All specimens, which were
pathologically primary tumours, included cancerous tis-
sues and matched clear surgical margin tissues typically
4-15 mm in diameter, and 9 cases also contained meta-
static lymph node tissues. All specimens were frozen after
collection and stored at -80°C immediately. All patients
who donated specimens were monitored after the sur-
gery. Among patients treated with total laryngectomy, no
recurrent signs were found. Among the patients who
underwent partial laryngectomy, local recurrence on the
surgical margin of 3 patients has been confirmed. Then,
total laryngectomy was performed on these patients and
no further neoplasm was found after 12 months follow-
up. On the other hand, neck masses have been observed
in 12 patients, and these masses exhibited regression
after radiotherapy. Because of the negative result from
the puncture biopsy and the lack of direct recurrent evi-
dence, we treated these patients as disease-free survivors.
Approval for the study was received from the Ethics
Committee of China Medical University. Patient informa-
tion is shown in Table 1.
Semi-quantitative reverse transcription-polymerase chain 
reaction (RT-PCR)
Total RNA was isolated with Trizol reagent according to
the instructions and cDNA was reversibly transcribed
from the isolated mRNA using an AMV RNA PCR kit
(TaKaRa, China) in line with the standard operating pro-
tocol. The upstream primer sequence for 14-3-3epsilon
was 5'-ACG ACG AAA TGG TGG AGT-3', and the
downstream sequence was 5'-AGC TGC TGG AAT GAG
GTG-3', which were expected to produce a 278-bp DNA
fragment. β-actin served as an internal control to ensure
that an equal amount of mRNA was analysed from each
sample. The upstream primer sequence for β-actin was
5'-CCA GAT CAT GTT TGA GAC CT-3', and down-
Table 1: The characteristics of the Patients (n = 101).
Characteristic No. of patients (%)
Age, years
< 62 51 (50.5)
≥ 62 50 (49.5)
Sex
Male 81 (80.2)
Female 20 (19.8)
Clinical Stages
I (T1N0M0) 19 (18.8)
II (T2N0M0) 19 (18.8)
III (T3N0M0, T1-3N1M0) 26 (25.7)
IV (T4aN0-1M0, T1-4aN2M0, T1-4N3M0, T4bN1-3M0, 
T1-4N1-3M1)
37 (36.7)
metastatic lymph nodes 9 (8.9)Che et al. BMC Cancer 2010, 10:306
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stream sequence was 5'-TTG AAG GTA GTT TCG TGG
AT-3', which were expected to produce a 480-bp DNA
fragment. The PCR reaction was performed in a 25-μl
system, starting with denaturation at 94°C for 3 min, then
30 cycles of denaturation at 94°C for 30 sec, annealing at
56°C for 45 sec, and extension at 72°C for 45 sec, followed
by an extra extension at 72°C for 10 min. The PCR prod-
ucts were separated by 1.2% agarose gel electrophoresis,
stained with ethidium bromide and photographed.
Western blot
For sample preparation, 100 mg of tissue was taken from
each sample and ground to a powdery preparation with
liquid nitrogen. Twenty micrograms of each sample was
lysed by 250 μl of protein extracting fluid (RIPA Lysis
Buffer: 50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-
100, 1% sodium deoxycholate, 0.1% SDS; PMSF),
homogenised for 10 min, incubated in an ice-bath for 1 h,
and centrifuged at 12,000 g for 30 min at 4°C. The super-
natant was finally collected, and the protein concentra-
tion was determined using the BCA protein assay system
(Pierce, Rockford, Illinois, USA). Proteins (50 μg/lane)
were separated by 12% sodium dodecyl sulphate-poly-
acrylamide gel electrophoresis (SDS-PAGE) and then
transferred to PVDF membranes. After blocking over-
night at 4°C with 1× PBS with 0.1% Tween 20 and 5%
non-fat milk, the membranes were incubated with 14-3-
3epsilon polyclonal antibody (1:800, Santa Cruz, USA)
for 3 h at room temperature, washed twice and then incu-
bated again with horseradish peroxidase-conjugated goat
anti-rabbit secondary antibody (ZhongShan, China,
1:1,500) for 2 h at room temperature. Immunodetection
was performed with chemiluminescence (ECL reagent,
Beyotime, China) and the membranes were exposed to
film. The image was obtained with a transmission scan-
ner. For quantification, the target proteins were norma-
lised to the internal standard protein β-tubulin by
comparing the gray-scale values of 14-3-3epsilon to β-
tubulin, which were analysed with the UVP Gelworks ID
advanced version 2.5 software (Bio-Rad, USA) [10].
Construction of 14-3-3epsilon-GFP expression vector
The entire open reading frame of 14-3-3epsilon comple-
mentary DNA (cDNA) was obtained by RT-PCR from
mRNA of Hep-2 cells. The forward primer used in the
PCR reaction was 5'-ttt AGA TCT tcc gct tcc atc cgt c-3',
which included a Bgl II site (the capital letters) at the 5'
end. The reverse primer was 5'-g tgt ccc tGA ATT Ctc ttg
ttg gct tat-3', which contained a EcoR I site (the capital
letters) at the 5' end. The PCR product covered the initia-
tion codon and its flanking sequences. The PCR reaction
was performed in a 50-μl reaction system, starting with
denaturation at 94°C for 3 min, then 35 cycles of denatur-
ation at 94°C for 30 sec, annealing at 60°C for 45 sec, and
extension at 72°C for 1 min, followed by an extra exten-
sion at 72°C for 10 min. The amplified fragments were
digested with Bgl II and EcoR I and cloned into pEGFP-C1
plasmids (BD, USA). The 14-3-3epsilon-GFP expression
vector was verified by Bgl II-EcoR I digestion and DNA
sequencing. 14-3-3epsilon was expressed by fusion to the
C-terminus of EGFP.
Cell culture and Transient Transfection
The Hep-2 (Human laryngeal carcinoma) cell line was
purchased from Cell Biology Institute of Shanghai, Chi-
nese Academy of Science and originated from a meta-
static epidermoid carcinoma of the larynx [11]. The cells
were maintained in RPMI-1640 supplemented with 10%
foetal bovine serum (FBS), 100 U/mL penicillin and 100
μg/mL streptomycin at 37°C in a humidified atmosphere
of 5% CO2 and 95% air. Upon reaching 60%-70% conflu-
ence, the cells were seeded overnight at a density of 1 ×
105 cells per well in six-well plates. 14-3-3epsilon-GFP
vectors and pEGFP-C1 vectors (as a negative control)
were then transfected into Hep-2 cells using Lipo-
fectamine 2000 (Invitrogen, USA) following the manufac-
turer's instructions. After 24 h of transfection, the
effectiveness of transfection was observed and detected
by fluorescence microscopy and RT-PCR, respectively.
Cell viability assay
After being seeded for 24 h in a 96-well plate, Hep-2 cells
(1 × 104 cells/well) were transfected with GFP and 14-3-
3epsilon-GFP for 48 h in 3 parallel wells each, with
untransfected cells serving as a control. At 48 h, 10 μl of
MTT solution (5 mg/mL) was added to each well and
incubated for a further 4 h. The medium was removed
and 200 μl of DMSO was added to each well and then
vibrated for 10 min. Absorbance (A) at 490 nm was mea-
sured using a microplate reader. The percentage of viable
cells was calculated as follows: (A of experimental group/
A of control group) × 100%. Data were indicated as the
means of the triplicate determinations [10].
Cell cycle assay
After incubation at 37°C for 48 h, cells were harvested in
cold PBS and washed once with 1× PBS, fixed in 70%
EtOH, and stored at 4°C for 24 h. The fixed cells were
washed with 1× PBS once, suspended in 400 μl of 50 mg/
ml PI staining reagent (Sigma, USA), and then incubated
in the dark for 30 min. The distribution and quantitation
of cells in cell cycle distribution were detected by flow
cytometry [10].
Apoptosis assay
The apoptotic rates were analysed by flow cytometry
using an annexin V-PE/7-AAD Kit (KeyGEN, China).
Staining was performed according to the manufacturer's
instructions, and flow cytometry was conducted on aChe et al. BMC Cancer 2010, 10:306
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FACSCalibur (Becton Dickinson, Mountain View, NJ,
USA). Cells that were both annexin V-PE and 7-AAD
negative were considered viable cells. Cells that were
annexin V-PE positive and 7-AAD negative indicated
early apoptotic cells. Cells that were both annexin V-PE
and 7-AAD positive represented late apoptotic cells [10].
Transwell chamber invasion assay
Twenty-four-well invasion chambers were obtained from
Costar. Hep-2 cells transfected with negative control GFP
and 14-3-3epsilon-GFP were detached from the tissue
culture plates, washed, resuspended in conditioned
medium (2 × 105 cells/ml), and added to the upper com-
partment of the invasion chamber. Five hundred
microlitres of conditioned medium was added to the
lower compartment of the invasion chamber. The inva-
sion chambers were then incubated at 37°C for 24 h. After
incubation, the inserts and cells on the upper side of the
filter were removed. The filters were fixed, mounted, and
stained according to the manufacturer's instructions. The
cells that invaded to the underside of the filter were
counted. Each experiment was repeated three times. The
values obtained were calculated by averaging the total
number of cells from triplicate determinations [12].
Statistical analysis
Statistical analysis was performed using SPSS 17.0. All
data were expressed as means ± standard error of the
mean (SEM). The comparisons between mRNA and pro-
tein expression levels in one group between tumour and
matched clear surgical margin tissues and in the other
group between tumour and metastatic lymph nodes were
made by the paired sample t-test for parametric analysis
or Wilcoxon signed rank test for nonparametric analysis.
Comparisons related to age or sex in clinical characteris-
tics were made by the Mann-Whiney U test. The differ-
ences between experimental and control groups and
among gene expression levels related to clinical stages
were analysed by one-way analysis of variance (ANOVA).
The correlation between mRNA and protein levels was
analysed by Spearman rank correlation. Statistical signifi-
cance was assumed for a two-tailed p < 0.05.
Results
Reduced expression of 14-3-3epsilon in LSCC
14-3-3epsilon  mRNA levels in 72 of the 101 cases of
LSCC and matched clear surgical margin tissues were
evaluated by RT-PCR. The result showed that the 14-3-
3epsilon mRNA expression level in LSCC tissues was sig-
nificantly lower than that in clear surgical margin tissues
(p = 0.008, Figure 1A and Table 2). 14-3-3epsilon protein
levels were detected in all 101 cases of LSCC tissues and
matched clear surgical margin tissues and in all 9 cases of
metastatic lymph node tissues by western blotting. The
14-3-3epsilon protein expression level in LSCC tissues
was significantly lower than that in clear surgical margin
tissues (p = 0.002, Figure 1B and Table 2). However, there
was no significant correlation between mRNA levels and
protein levels (data not shown). The 14-3-3epsilon pro-
tein expression level in the metastatic lymph nodes was
also lower than that in matched LSCC tissues (p = 0.037,
Figure 1C and Table 3).
We assessed the 14-3-3epsilon expression levels with
respect to clinical characteristics (age, sex and the clinical
stages). No differences were identified in protein and
mRNA levels of 14-3-3epsilon with respect to patient age
and sex (data not shown). There was no difference in
mRNA levels with respect to patient clinical stage (Table
4). However, the protein expression level of 14-3-3epsilon
in stage III or IV tumours was significantly lower than
that in any stage I or II tumours (p < 0.001, Table 4).
Decreased proliferation of Hep-2 cells transfected with 14-
3-3epsilon
Hep-2 cells were transfected with 14-3-3epsilon-GFP and
GFP expression vectors. Twenty-four hours after trans-
fection, Hep-2 cells in the 14-3-3epsilon-GFP group
showed a significant increase in 14-3-3epsilon expression
at both mRNA (Figure 2A, p < 0.05) and protein levels
compared to those in the blank and negative groups (Fig-
ure 2B and 2C). As shown in Figure 3, the percentages of
viable cells in 14-3-3epsilon-GFP and negative control
GFP groups compared to that in blank group were 36.68
± 14.09% and 71.68 ± 12.10%, respectively, which indi-
cated that the growth of Hep-2 cells decreased signifi-
cantly after 14-3-3epsilon-GFP transfection (p = 0.008).
S phase arrest of Hep-2 cells with overexpression of 14-3-
3epsilon
Compared with the blank control (Figure 4A) and nega-
tive control GFP groups (Figure 4B), a significant accu-
mulation of cells in the S phase of the cell cycle and a
concomitant increase in the apoptotic sub-G1 population
were noted in the 14-3-3epsilon-GFP group (Figure 4C).
In the control, negative and 14-3-3epsilon-GFP groups,
the proportions of S phase cells were 22.47 ± 3.36%, 28.17
± 3.97% and 46.15 ± 6.82%, respectively (p = 0.034, Figure
4D) and the apoptotic sub-G1 population significantly
increased from 1.23 ± 1.02% and 2.92 ± 1.59% in the con-
trol and negative groups, respectively, to 13.72 ± 3.89% in
the 14-3-3epsilon-GFP group (p = 0.024, Figure 4E).
Increased apoptosis of Hep-2 cells transfected with 14-3-
3epsilon
Compared with blank control (Figure 5A) and negative
control GFP groups (Figure 5B), the number of the late
apoptotic cells significantly increased in 14-3-3epsilon-
GFP group cells (Figure 5C). The percentages of theChe et al. BMC Cancer 2010, 10:306
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apoptotic cells in control, negative and 14-3-3epsilon-
GFP groups were 0.84 ± 0.25%, 1.08 ± 0.24% and 2.93 ±
0.13%, respectively, which showed significant differences
among the different groups (p < 0.001, Figure 5D).
Decreased invasiveness in Hep-2 cells transfected with 14-
3-3epsilon
Compared to those in the blank control (Figure 6A) and
negative control GFP groups (Figure 6B), the number of
cells migrating across the membranes in the 14-3-
3epsilon-GFP group (Figure 6C) decreased dramatically.
The numbers of cells penetrating the filter membrane in
the control, negative and 14-3-3epsilon-GFP groups were
20.65 ± 1.94, 17.63 ± 1.04 and 9.1 ± 0.24, respectively,
which showed significant differences among the different
groups (p < 0.001, Figure 6D).
Discussion
14-3-3epsilon is a member of the 14-3-3 protein family
comprising a series of highly conserved small acidic pro-
teins of about 29-33 kDa. 14-3-3 proteins, which were
originally identified as brain-specific, are present in a
wide range of organisms and tissues. These proteins nor-
mally exist as homo- or heterodimers. The 14-3-3 dimer
serves as an adaptor that couples with target proteins to
Figure 1 Expression of 14-3-3epsilon in LSCC. A. 14-3-3epsilon mRNA levels in LSCC. B and C. 14-3-3epsilon protein levels in LSCC. M, DNA marker; 
T, tumour; R, clear surgical margin; N, metastatic lymph node tissues.
Table 2: Analysis of 14-3-3epsilon mRNA and protein levels in tumour and clear surgical margin tissues.a
Tissues 14-3-3epsilon mRNA 14-3-3epsilon protein
Tumour 0.9284 ± 0.0938 1.8003 ± 0.1867
Clear surgical margin 1.6822 ± 0.2447 2.9328 ± 0.3675
p-value 0.008 0.002
aGray-scale ratio, mean ± SEM, n = 72 n = 101Che et al. BMC Cancer 2010, 10:306
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stimulate protein-protein interactions, regulate the sub-
cellular localisation of proteins and activate or inhibit
associated enzymes. The binding between a 14-3-3 pro-
tein and its substrate is generally triggered by phosphory-
lation of the target protein at specific Ser/Thr residues. In
this manner, 14-3-3 proteins are key regulators of phos-
phoprotein targets within a variety of processes, such as
the regulation of cell signalling, cell cycle progression,
signal transduction, intracellular trafficking/targeting,
cytoskeletal structure, transcription and apoptosis [13-
17].
14-3-3epsilon also regulates a wide range of biological
processes. Abnormal expression of 14-3-3epsilon  has
been found in several types of cancers. Low expression of
14-3-3epsilon occurred in lung cancers [18] and medullo-
blastoma [19]. High expression of 14-3-3epsilon  was
detected in subependymomas [20]. At present, there are
few clues about the role and molecular mechanism of 14-
3-3epsilon in carcinogenesis, and no information of 14-3-
3epsilon related to LSCC has been reported.
In this study, the general tendency of 14-3-3epsilon
mRNA and protein expression levels was consistent,
which means that 14-3-3epsilon  expression at both
mRNA and protein levels was down-regulated in LSCC
compared with those in the clear surgical margin tissues.
However, there was no significant correlation between
mRNA and protein levels in LSCC, which could be
caused by mechanisms such as inhibition of microRNAs
in translation. There was also no relationship between
14-3-3epsilon expression levels and sex or age in patients
suffering with LSCC, which shows that sex and age do
not affect the expression levels of 14-3-3epsilon in LSCC.
Although there was no significant difference between 14-
3-3epsilon protein levels at stage III and IV or stage I and
II, a significant difference between 14-3-3epsilon protein
levels at stage III or IV and those at stage I or II in LSCC
was observed, which indicates that the 14-3-3epsilon pro-
tein may be useful in identifying metastatic or locally
advanced LSCC tumours.
14-3-3epsilon plays a role in the G2 DNA damage
checkpoint response, which results in G2 phase arrest in
different cancer cell lines due to inhibition of cdc25C
[18,21,22]. However, our study showed that the growth of
Hep-2 cells overexpressing 14-3-3epsilon was inhibited
and these cells were only halted in S phase, which indi-
cates that the low proliferation of Hep-2 cells transfected
with 14-3-3epsilon-GFP originates partly from S phase
arrest. The molecular mechanism of how the arrest of
Hep-2 cells in S phase is affected by 14-3-3epsilon will be
an interesting area of future study.
Some studies show that 14-3-3epsilon, an inhibitor of
apoptosis proteins, prevents apoptosis progression by
inhibiting the activities of pro-apoptotic proteins such as
Bad and Bax [23-26]. However, in the present study, our
results from both apoptosis and cell cycle assays showed
that the number of apoptotic cells in the 14-3-3epsilon-
GFP group increased, which indicates that 14-3-3epsilon
can promote apoptosis. We speculate that the increased
apoptosis in Hep-2 cells transfected with 14-3-3epsilon
could also lead to a reduction of cell numbers. Mean-
while, the down-regulation of 14-3-3epsilon detected in
LSCC in the study perhaps indicates a role for 14-3-
Table 3: Analysis of 14-3-3epsilon protein levels in tumour 
and metastatic lymph node tissues.a
Tissues 14-3-3epsilon protein
Tumour 1.6460 ± 0.3897
metastatic lymph nodes 0.8040 ± 0.2006
p-value 0.037
aGray-scale ratio, mean ± 
SEM
n = 9
Table 4: Analysis of the relationship between 14-3-3epsilon and Clinical Stages.a
Clinical stages 14-3-3epsilon mRNA 14-3-3epsilon protein
I 1.1288 ± 0.2341 3.0582 ± 0.5554
II 0.9747 ± 0.1976 2.8348 ± 0.5532
III 0.6006 ± 0.1414 1.1029 ± 0.1744
IV 0.9661 ± 0.1609 1.1132 ± 0.1763
p-value 0.342 < 0.001
aGray-scale ratio, mean ± SEMChe et al. BMC Cancer 2010, 10:306
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3epsilon in the development of LSCC by inhibiting apop-
tosis.
Normal tissue invasion and metastasis are hallmarks of
malignant tumours. Cancer cell metastasis to distant
organs is the major cause of death in almost all forms of
cancer. Metastasis is a multi-step process, and the initial
step is the invasion of surrounding tissues by cancer cells.
Inhibition of the invasion and metastasis pathways of
tumour cells could provide new treatment alternatives for
cancer patients [27,28]. Tak et al. found that 14-3-
3epsilon inhibits cell migration in HeLa cells by interact-
ing with MAPK-activated protein kinase 5 (MK5) [29].
Our present study showed that 14-3-3epsilon displayed
lower expression in the metastatic lymph nodes com-
pared to that in cancer tissues and 14-3-3epsilon protein
levels were significantly lower in stage III or IV compared
to those in stage I or II, which implies that 14-3-3epsilon
might inhibit the metastasis of LSCC. Additionally, our
transwell result supports this conclusion. The results
from apoptosis, cell cycle and cell viability assays com-
bined with those mentioned above in the study implies
that the lower expression of 14-3-3epsilon that results in
decreased apoptosis and high proliferation could contrib-
ute to invasion and aggression of LSCC.
According to the achieved results in the present study,
14-3-3epsilon could be a useful parameter for diagnosing
LSCC. It could also be used as a molecular marker to
determine clinical staging. Meanwhile, 14-3-3epsilon
may be a potential target of a new drug that can control
the initiation and progression of LSCC effectively.
Conclusions
Decreased expression of 14-3-3epsilon in LSCC tissues
contributes to the initiation and progression of LSCC. 14-
3-3epsilon can promote apoptosis and inhibit the inva-
siveness of LSCC. The exact molecular mechanisms of
14-3-3epsilon  in apoptosis and aggression of LSCC
require further investigation.
Figure 2 Transfection of 14-3-3epsilon in Hep-2 cells. A. mRNA levels of 14-3-3epsilon in Hep-2 cells transfected with 14-3-3epsilon-GFP. B. GFP as 
a negative control was revealed by contrast and fluorescence microscopy under the same phase. C. Transfected 14-3-3epsilon-GFP was revealed by 
contrast and fluorescence microscopy under the same phase. Lanes: M, DNA marker; cell, control cells; GFP, negative control of GFP; 14-3-3epsilon, 
transfected 14-3-3epsilon-GFP (*p < 0.05).
Figure 3 The proliferation of Hep-2 cells. A. The percentage of via-
ble Hep-2 cells before transfection. B. The percentage of viable Hep-2 
cells after transfection with GFP. C. The percentage of viable Hep-2 
cells after transfection with 14-3-3epsilon-GFP (*p < 0.05).Che et al. BMC Cancer 2010, 10:306
http://www.biomedcentral.com/1471-2407/10/306
Page 8 of 10
Figure 4 Cell cycle control of Hep-2 cells. A. Cell cycle analysis of Hep-2 cells before transfection. B. Cell cycle analysis of Hep-2 cells transfected with 
GFP. C. Cell cycle analysis of Hep-2 transfected with 14-3-3epsilon-GFP. D. The percentages of cells in S phase from the blank, GFP and 14-3-3epsilon-
GFP groups, respectively (*p < 0.05). E. The proportions of cells in apoptotic sub-G1 phase from the blank, GFP and 14-3-3epsilon-GFP groups, respec-
tively (*p < 0.05).
Figure 5 Late apoptosis of Hep-2 cells. A. Apoptotic chart of Hep-2 cells before transfection. B. Apoptotic chart of Hep-2 cells transfected with GFP. 
C. Apoptotic chart of Hep-2 transfected with 14-3-3epsilon-GFP. D. The percentages of late apoptotic cells in the blank, GFP and 14-3-3epsilon-GFP 
groups, respectively (*p < 0.05).Che et al. BMC Cancer 2010, 10:306
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